triallosses

218 results found.

Top Stocks matching your search for "trial losses"

Click Learn More to know about Stock Advisor's top picks. We've 3x'd the S&P 500 over the last 20 years.

02/0902/1402/1702/2302/2803/0303/0803/1303/1603/21
SAVA

Cassava Sciences Inc

-13.96%

$29.88 - $25.71

Feb 7th 2023 - Mar 21st 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

Mar, 15, 2023

$SAVA “Treatment also eased depression and dementi... See more

Feb, 6, 2023

Simufilam reduced dementia-related behavior at 9 m... See more

02/0902/1402/1702/2302/2803/0303/0803/1303/1603/21
BXRX

Baudax Bio Inc

-52.79%

$3.41 - $1.61

Feb 7th 2023 - Mar 21st 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

Mar, 16, 2023

By utilizing a specialized database, this study is... See more

Feb, 16, 2023

$NRBO check out all of the trials they have going ... See more

02/0902/1402/1702/2302/2803/0303/0803/1303/1603/21
PALI

Palisade Bio Inc

-19.56%

$2.25 - $1.81

Feb 7th 2023 - Mar 21st 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

Jan, 2, 2023

They voluntarily suspended phase 3 bc they are see... See more

Dec, 16, 2022

$PALI phase 2 coming WOOOOO!! !

SAVA

Cassava Sciences Inc

-13.96%

$29.88 - $25.71

Feb 7th 2023 - Mar 21st 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

Mar, 15, 2023

$SAVA “Treatment also eased depression and dementia-related behaviors in patients, two exploratory trial goals, and simufilam was found to be safe and well tolerated.”

Feb, 6, 2023

Simufilam reduced dementia-related behavior at 9 months on the Neuropsychiatric Inventory (NPI), a clinical tool widely used to measure changes in dementia-related behavior.

Feb, 1, 2023

The open label study is a true gift which gives us insight on both health and benefit issues and the med looks great on both counts.

Jan, 17, 2023

$SAVA September 3rd 2021 Remi Barbier said, "I truly believe Cassava Sciences is one clinical program away from greatness.

Jan, 6, 2023

$SAVA Per press release dec 6 2022, Remi stated administration of drug for OL study completed and he is "THRILLED" with the clinical development, or what he see to this date.

Jan, 4, 2023

$SAVA , VERA announced positive phase 2b results meeting primary end point.

Dec, 27, 2022

My prediction: Phase 2 Unbelievable results FDA fast track Phase 3 - go ahead Patients receive sava Market cap 40 B by 2024 Rising to 200 Billion by 2026 Game changer - the only drug in the world to help patients

BXRX

Baudax Bio Inc

-52.79%

$3.41 - $1.61

Feb 7th 2023 - Mar 21st 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

Mar, 16, 2023

By utilizing a specialized database, this study is ensuring the utmost safety and efficacy of the medication.

Feb, 16, 2023

$NRBO check out all of the trials they have going on and backed by DONG A-ST this is the making of a MEGA RUNNER.

Jan, 24, 2023

Successful phase 2 which will be final approved April 2023 .

Jan, 14, 2023

3.67 cash per share and $20+ PT's. Not to mention, consistency with positive studies and data.

Jan, 13, 2023

Phase 3 results were solid.

Jan, 3, 2023

$BXRX must be good phase 2 data

Dec, 9, 2022

I can only imagine how useful it will be clinical setting, much like a Toradol Injection is used.

Dec, 8, 2022

$SNAP $META $GOOGL $PINS gonna go up $BXRX is just getting started imo huge phase 2 trial and great fundamentals

Dec, 8, 2022

$AFRM $UPST $SOFI $DLO good fintech companies $BXRX holy shiiii amazing news with starting their trials and great fundamentals

PALI

Palisade Bio Inc

-19.56%

$2.25 - $1.81

Feb 7th 2023 - Mar 21st 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

Jan, 2, 2023

They voluntarily suspended phase 3 bc they are seeing such a good results.

Dec, 16, 2022

$PALI phase 2 coming WOOOOO!! !

Nov, 22, 2022

$PALI approaching alpha Centauri phase 🪐